All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
The ins and outs of CAR T cells in the real world: Live Hub event
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
During the European Hematology Association (EHA) 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite session on the ins and outs of CAR T-cells in the real world.
Here the Multiple Myeloma Hub is pleased to share a real-world patient case as presented by Doris Hansen, Moffitt Cancer Center, Tampa, US.
Real-world patient cases: CAR T-cell therapy
Here, Hansen discusses a case study of a 78-year-old caucasian male with multiple comorbidities and prior exposure to a BCMA-directed agent (Figure 1), they were treated with idecabtagene vicleucel (ide-cel). Hansen uses the case study to examine real-world safety and efficacy data for both ide-cel (Figure 2) and ciltacabtagene autoleucel (cilta-cel), making comparisons with clinical trial data from KarMMa and CARTITUDE-1.1
Figure 1. Patient case study outline*
BCMA, B-cell maturation antigen; CAD/NSTEMI, coronary artery disease/non-ST-elevation myocardial infarction; CAR, chimeric antigen receptor; cyclo; cyclophosphamide; dara, daratumumab; d, dexamethasone; ECOG, Eastern Cooperative Oncology Group; EF, ejection fraction; HCT, hematopoietic stem cell transplant; IDDM, insulin-dependent diabetes mellitus 2; ide-cel, idecabtagene vicleucel; Ig, immunoglobulin; Isa, isatuximab; Ixa, ixazomib; K, carfilzomib; MM, multiple myeloma; P, pomalidomide; R, lenalidomide; R-ISS, revised International Staging System; s/p, status post; T, thalidomide; V, bortezomib
*Provided by Hansen.1
Figure 2. Safety of ide-cel in the real-world setting*
CRS, cytokine release syndrome; ide-cel, idecabtagene vicleucel; NRM, non-relapse mortality; NT, neurotoxicity; SOC, standard of care.
*Adapted from Hansen, et al.2
†ASTCT criteria used for grading CRS and NT.
Watch or download the presentation to learn more about:
This activity was supported through an educational grant from Bristol Myers Squibb.
The ins and outs of CAR T cells in the real world: Live Hub event
Subscribe to get the best content related to multiple myeloma delivered to your inbox